<?xml version="1.0" encoding="UTF-8"?>
<!-- generated by CLiX/Wiki2XML [MPI-Inf, MMCI@UdS] $LastChangedRevision: 92 $ on 16.04.2009 16:26:32[mciao0825] -->
<!DOCTYPE article SYSTEM "../article.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink">
<invention  confidence="0.9511911446218017" wordnetid="105633385">
<agent  confidence="0.9511911446218017" wordnetid="109190918">
<header>
<title>Propranolol</title>
<id>185848</id>
<revision>
<id>243851676</id>
<timestamp>2008-10-08T09:35:03Z</timestamp>
<contributor>
<username>Toby Bartels</username>
<id>1078</id>
</contributor>
</revision>
<categories>
<category>Anxiolytics</category>
<category>Scottish inventions</category>
<category>Beta blockers</category>
<category>Antiarrhythmic agents</category>
</categories>
</header>
<bdy>

<table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" width="280" align="right" cellpadding="1" class="toccolours" border="0">

<row>
<col colspan="2" align="center">
 <image width="150px" src="Propranolol-2D-skeletal.png">
<caption>

 220px 
</caption>
</image>
</col>
</row>
<row>
<col colspan="2" align="center">
 <image width="150px" src="Propranolol-from-xtal-3D-balls.png">
<caption>

 180px 
</caption>
</image>
</col>
</row>
<row>
<col colspan="2" align="center">
Propranolol</col>
</row>
<row>
<col colspan="2" align="center" bgcolor="#dddddd">
 <b>Systematic (<link xlink:type="simple" xlink:href="../503/3141503.xml">
IUPAC</link>) name</b></col>
</row>
<row>
<col colspan="2" style="text-align: center; vertical-align: top;" bgcolor="#eeeeee">
1-(isopropylamino)-3-(naphthalen-1-yloxy)propan-2-ol</col>
</row>






<row>
<col colspan="2" bgcolor="#dddddd">
<b>Identifiers</b></col>
</row>
<row>
<col width="90" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../815/160815.xml">
CAS number</link></col>
<col bgcolor="#eeeeee">
 <weblink xlink:type="simple" xlink:href="http://www.nlm.nih.gov/cgi/mesh/2008/MB_cgi?term=525-66-6&amp;rn=1">
525-66-6</weblink></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../770/2770.xml">
ATC code</link></col>
<col bgcolor="#eeeeee">
 <written_communication wordnetid="106349220" confidence="0.8">
<code wordnetid="106667317" confidence="0.8">
<link>
C07</link></code>
</written_communication>
<weblink xlink:type="simple" xlink:href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=C07AA05">
AA05</weblink></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <institute wordnetid="108407330" confidence="0.8">
<association wordnetid="108049401" confidence="0.8">
<link xlink:type="simple" xlink:href="../723/2863723.xml">
PubChem</link></association>
</institute>
</col>
<col bgcolor="#eeeeee">
 <weblink xlink:type="simple" xlink:href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=4946">
4946</weblink></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../731/3408731.xml">
DrugBank</link></col>
<col bgcolor="#eeeeee">
 <weblink xlink:type="simple" xlink:href="http://www.drugbank.ca/cgi-bin/show_drug.cgi?CARD=APRD00194">
APRD00194</weblink></col>
</row>

<row>
<col colspan="2" bgcolor="#dddddd">
<b>Chemical data</b></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../043/7043.xml">
Formula</link></col>
<col bgcolor="#eeeeee">
 <link xlink:type="simple" xlink:href="../299/5299.xml">
C</link>16<link xlink:type="simple" xlink:href="../255/13255.xml">
H</link>21<link xlink:type="simple" xlink:href="../175/21175.xml">
N</link><link xlink:type="simple" xlink:href="../303/22303.xml">
O</link>2&nbsp;</col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../836/19836.xml">
Mol. mass</link></col>
<col bgcolor="#eeeeee">
259.34 g/mol</col>
</row>









<row>
<col colspan="2" bgcolor="#dddddd">
<b>Pharmacokinetic data</b></col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../021/769021.xml">
Bioavailability</link></col>
<col bgcolor="#eeeeee">
26%</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../475/1173475.xml">
Metabolism</link></col>
<col bgcolor="#eeeeee">
 <link xlink:type="simple" xlink:href="../301/17384301.xml">
hepatic</link>(extensive)</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../099/3206099.xml">
Half life</link></col>
<col bgcolor="#eeeeee">
4-5 hours</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../468/255468.xml">
Excretion</link></col>
<col bgcolor="#eeeeee">
 <link xlink:type="simple" xlink:href="../025/17025.xml">
renal</link>1%</col>
</row>
<row>
<col colspan="2" bgcolor="#dddddd">
<b>Therapeutic considerations</b></col>
</row>
<row>
<col bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../840/1186840.xml">
Licence data</link></col>
<col bgcolor="#eeeeee">
<weblink xlink:type="simple" xlink:href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&amp;SearchTerm=Propranolol&amp;SearchType=BasicSearch">
US</weblink></col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../622/588622.xml">
Pregnancy cat.</link></col>
<col bgcolor="#eeeeee">
  
C(<country wordnetid="108544813" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../264/4689264.xml">
AU</link></country>
) C(<body wordnetid="107965085" confidence="0.8">
<social_group wordnetid="107950920" confidence="0.8">
<political_orientation wordnetid="106212839" confidence="0.8">
<colony wordnetid="108374049" confidence="0.8">
<state wordnetid="108168978" confidence="0.8">
<political_unit wordnetid="108359949" confidence="0.8">
<group wordnetid="100031264" confidence="0.8">
<democracy wordnetid="106217103" confidence="0.8">
<link xlink:type="simple" xlink:href="../750/3434750.xml">
US</link></democracy>
</group>
</political_unit>
</state>
</colony>
</political_orientation>
</social_group>
</body>
)</col>
</row>
<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <link xlink:type="simple" xlink:href="../840/1186840.xml">
Legal status</link></col>
<col bgcolor="#eeeeee">
    
<link xlink:type="simple" xlink:href="../716/2458716.xml#xpointer(//*[./st=%22Schedule+4+Prescription+Only+Medicine%22])">
Prescription Only (S4)</link>(<country wordnetid="108544813" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../264/4689264.xml">
AU</link></country>
) <link xlink:type="simple" xlink:href="../238/359238.xml">
POM</link>(<autocracy wordnetid="108361001" confidence="0.8">
<system wordnetid="108435388" confidence="0.8">
<social_group wordnetid="107950920" confidence="0.8">
<political_orientation wordnetid="106212839" confidence="0.8">
<monarchy wordnetid="108363812" confidence="0.8">
<state wordnetid="108168978" confidence="0.8">
<political_unit wordnetid="108359949" confidence="0.8">
<political_system wordnetid="108367880" confidence="0.8">
<economy wordnetid="108366753" confidence="0.8">
<group wordnetid="100031264" confidence="0.8">
<democracy wordnetid="106217103" confidence="0.8">
<link xlink:type="simple" xlink:href="../717/31717.xml">
UK</link></democracy>
</group>
</economy>
</political_system>
</political_unit>
</state>
</monarchy>
</political_orientation>
</social_group>
</system>
</autocracy>
) <link xlink:type="simple" xlink:href="../238/359238.xml">
â„ž-only</link>(<body wordnetid="107965085" confidence="0.8">
<social_group wordnetid="107950920" confidence="0.8">
<political_orientation wordnetid="106212839" confidence="0.8">
<colony wordnetid="108374049" confidence="0.8">
<state wordnetid="108168978" confidence="0.8">
<political_unit wordnetid="108359949" confidence="0.8">
<group wordnetid="100031264" confidence="0.8">
<democracy wordnetid="106217103" confidence="0.8">
<link xlink:type="simple" xlink:href="../750/3434750.xml">
US</link></democracy>
</group>
</political_unit>
</state>
</colony>
</political_orientation>
</social_group>
</body>
)</col>
</row>

<row>
<col style="vertical-align: top;" bgcolor="#ddeeff">
 <work wordnetid="100575741" confidence="0.8">
<treatment wordnetid="100658082" confidence="0.8">
<event wordnetid="100029378" confidence="0.8">
<care wordnetid="100654885" confidence="0.8">
<act wordnetid="100030358" confidence="0.8">
<psychological_feature wordnetid="100023100" confidence="0.8">
<activity wordnetid="100407535" confidence="0.8">
<link xlink:type="simple" xlink:href="../816/334816.xml">
Routes</link></activity>
</psychological_feature>
</act>
</care>
</event>
</treatment>
</work>
</col>
<col bgcolor="#eeeeee">
 oral, <link xlink:type="simple" xlink:href="../769/178769.xml">
iv</link></col>
</row>
</table>

<b>Propranolol</b> (<link xlink:type="simple" xlink:href="../768/611768.xml">
INN</link>) is a non-selective <link xlink:type="simple" xlink:href="../150/180150.xml">
beta blocker</link> mainly used in the treatment of <link xlink:type="simple" xlink:href="../432/77432.xml">
hypertension</link>. It was the first successful beta blocker developed. It is the only drug proven effective for the <link xlink:type="simple" xlink:href="../621/186621.xml">
prophylaxis</link> of migraines in children.  Propranolol is available in generic form as propranolol hydrochloride, as well as an <company wordnetid="108058098" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../872/441872.xml">
AstraZeneca</link></company>
 and <company wordnetid="108058098" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../147/2821147.xml">
Wyeth</link></company>
 product under the <link xlink:type="simple" xlink:href="../404/230404.xml">
trade name</link>s Inderal, Inderal LA, Avlocardyl, Deralin, Dociton, Inderalici, InnoPran XL, Sumial (depending on marketplace and release rate).
<sec>
<st>
 History and development</st>
<p>

<country wordnetid="108544813" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../994/26994.xml">
Scottish</link></country>
 scientist and St. Andrews graduate <physical_entity wordnetid="100001930" confidence="0.8">
<person wordnetid="100007846" confidence="0.8">
<acquirer wordnetid="109764201" confidence="0.8">
<scientist wordnetid="110560637" confidence="0.8">
<recipient wordnetid="109627906" confidence="0.8">
<educator wordnetid="110045713" confidence="0.8">
<doctor wordnetid="110020890" confidence="0.8">
<creator wordnetid="109614315" confidence="0.8">
<associate wordnetid="109816771" confidence="0.8">
<chancellor wordnetid="109906986" confidence="0.8">
<communicator wordnetid="109610660" confidence="0.8">
<biologist wordnetid="109855630" confidence="0.8">
<laureate wordnetid="110249011" confidence="0.8">
<negotiator wordnetid="110351874" confidence="0.8">
<peer wordnetid="109626238" confidence="0.8">
<honoree wordnetid="110183757" confidence="0.8">
<pharmacologist wordnetid="110421753" confidence="0.8">
<colleague wordnetid="109935990" confidence="0.8">
<adult wordnetid="109605289" confidence="0.8">
<health_professional wordnetid="110165109" confidence="0.8">
<inventor wordnetid="110214637" confidence="0.8">
<professional wordnetid="110480253" confidence="0.8">
<representative wordnetid="110522035" confidence="0.8">
<medical_practitioner wordnetid="110305802" confidence="0.8">
<pharmacist wordnetid="110421470" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<academician wordnetid="109759069" confidence="0.8">
<head_of_state wordnetid="110164747" confidence="0.8">
<link xlink:type="simple" xlink:href="../415/337415.xml">
James W. Black</link></head_of_state>
</academician>
</causal_agent>
</pharmacist>
</medical_practitioner>
</representative>
</professional>
</inventor>
</health_professional>
</adult>
</colleague>
</pharmacologist>
</honoree>
</peer>
</negotiator>
</laureate>
</biologist>
</communicator>
</chancellor>
</associate>
</creator>
</doctor>
</educator>
</recipient>
</scientist>
</acquirer>
</person>
</physical_entity>
 successfully developed propranolol in the late 1950s. He was awarded the <link xlink:type="simple" xlink:href="../502/52502.xml">
Nobel Prize in Medicine</link> for this discovery in 1988. Propranolol was derived from the early Î²-adrenergic antagonists <link xlink:type="simple" xlink:href="../019/4769019.xml">
dichloroisoprenaline</link> and <link xlink:type="simple" xlink:href="../859/18880859.xml">
pronethalol</link>. The key structural modification, which was carried through to essentially all subsequent beta blockers, was the insertion of an <link>
oxymethylene</link> bridge into the arylethanolamine structure of pronethalol thus greatly increasing the potency of the compound. This also apparently eliminated the <link xlink:type="simple" xlink:href="../445/6445.xml">
carcinogenicity</link> found with pronethalol in animal models.</p>

</sec>
<sec>
<st>
 Pharmacology </st>
<p>

Main article: <link xlink:type="simple" xlink:href="../150/180150.xml">
Beta blocker</link></p>
<p>

Propranolol is a <link xlink:type="simple" xlink:href="../150/180150.xml">
non-selective beta blocker</link>, that is, it blocks the action of <link xlink:type="simple" xlink:href="../250/10250.xml">
epinephrine</link> on both Î²1- and Î²2-<link xlink:type="simple" xlink:href="../017/241017.xml">
adrenergic receptor</link>s. It has little intrinsic sympathomimetic activity (ISA) but has strong membrane stabilizing activity (only at high blood concentrations, eg overdosage). Only L-propranolol is a powerful <link xlink:type="simple" xlink:href="../017/241017.xml">
adrenoceptor antagonist</link>, whereas D-propranolol is not. However, both have <link xlink:type="simple" xlink:href="../734/175734.xml">
local anesthetic</link> (termed topical) effect.</p>

</sec>
<sec>
<st>
 Pharmacokinetics </st>
<p>

Propranolol is rapidly and completely absorbed, with peak plasma levels achieved approximately 1â€“3 hours after ingestion. Co-administration with food appears to enhance bioavailability. Despite complete absorption, propranolol has a  variable <link xlink:type="simple" xlink:href="../021/769021.xml">
bioavailability</link> due to extensive <link xlink:type="simple" xlink:href="../539/1173539.xml">
first-pass metabolism</link>. <link xlink:type="simple" xlink:href="../301/17384301.xml">
Hepatic</link> impairment will therefore increase its bioavailability. The main metabolite 4-hydroxypropranolol, with a longer <link xlink:type="simple" xlink:href="../606/13606.xml">
half-life</link> (5.2â€“7.5 hours) than the parent compound (3â€“4 hours), is also pharmacologically active. </p>
<p>

Propranolol is a highly <link xlink:type="simple" xlink:href="../745/596745.xml">
lipophilic</link> drug achieving high concentrations in the brain. The duration of action of a single oral dose is longer than the half-life and may be up to 12 hours, if the single dose is high enough (e.g., 80 mg). Effective plasma concentrations are between 10â€“100 ng/mL.</p>
<p>

Toxic levels are associated with plasma concentrations above 2000 ng/ml</p>

</sec>
<sec>
<st>
 Clinical use </st>
<p>

<image location="right" width="150px" src="Propranolol_80mg.png" type="thumb">
<caption>

An 80mg capsule of Propranolol.
</caption>
</image>

Main article: <link xlink:type="simple" xlink:href="../150/180150.xml">
Beta blocker</link></p>

<ss1>
<st>
 Indications </st>
<p>

Propranolol is indicated for the management of various conditions including:<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref>
<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../432/77432.xml">
Hypertension</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../862/65862.xml">
Angina pectoris</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../562/5562.xml">
Tachyarrhythmia</link>s</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../969/60969.xml">
Myocardial infarction</link></entry>
<entry level="1" type="bullet">

Control of <link xlink:type="simple" xlink:href="../581/160581.xml">
tachycardia</link>/tremor associated with <link xlink:type="simple" xlink:href="../922/922.xml">
anxiety</link> and <link xlink:type="simple" xlink:href="../492/13492.xml">
hyperthyroidism</link> and <substance wordnetid="100019613" confidence="0.8">
<chemical wordnetid="114806838" confidence="0.8">
<part wordnetid="113809207" confidence="0.8">
<stabilizer wordnetid="115052667" confidence="0.8">
<material wordnetid="114580897" confidence="0.8">
<link xlink:type="simple" xlink:href="../390/5700390.xml">
lithium therapy</link></material>
</stabilizer>
</part>
</chemical>
</substance>
</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../528/10528.xml">
Essential tremor</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../035/21035.xml">
Migraine</link> prophylaxis</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../197/322197.xml">
Tension headache</link> (Off the label use)</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../284/242284.xml">
Tetralogy of Fallot</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../088/277088.xml">
Phaeochromocytoma</link> (along with <link xlink:type="simple" xlink:href="../667/18484667.xml">
Î± blocker</link>)</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../974/82974.xml">
Post Traumatic Stress Disorder</link> (experimental)</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../748/74748.xml">
Glaucoma</link></entry>
</list>
</p>
<p>

While once first-line treatment for <link xlink:type="simple" xlink:href="../432/77432.xml">
hypertension</link>, the role for beta-blockers was downgraded in June 2006 in the <autocracy wordnetid="108361001" confidence="0.8">
<system wordnetid="108435388" confidence="0.8">
<social_group wordnetid="107950920" confidence="0.8">
<political_orientation wordnetid="106212839" confidence="0.8">
<monarchy wordnetid="108363812" confidence="0.8">
<state wordnetid="108168978" confidence="0.8">
<political_unit wordnetid="108359949" confidence="0.8">
<political_system wordnetid="108367880" confidence="0.8">
<economy wordnetid="108366753" confidence="0.8">
<group wordnetid="100031264" confidence="0.8">
<democracy wordnetid="106217103" confidence="0.8">
<link xlink:type="simple" xlink:href="../717/31717.xml">
United Kingdom</link></democracy>
</group>
</economy>
</political_system>
</political_unit>
</state>
</monarchy>
</political_orientation>
</social_group>
</system>
</autocracy>
 to fourth-line as they perform less well than other drugs, particularly in the elderly, and evidence is increasing that the most frequently used beta-blockers at usual doses carry an unacceptable risk of provoking <link xlink:type="simple" xlink:href="../502/154502.xml">
type 2 diabetes</link>. <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%222%22])">2</ref></p>
<p>

Propranolol is also used to lower <link xlink:type="simple" xlink:href="../642/235642.xml">
portal vein</link> pressure in <link xlink:type="simple" xlink:href="../615/707615.xml">
portal hypertension</link> and prevent <link xlink:type="simple" xlink:href="../254/702254.xml">
oesophageal variceal</link> bleeding. </p>
<p>

Propranolol is often used by musicians and other performers to prevent <link xlink:type="simple" xlink:href="../102/600102.xml">
stage fright</link>.</p>
<p>

Propranolol is currently being investigated as a potential treatment for <link xlink:type="simple" xlink:href="../974/82974.xml">
post-traumatic stress disorder</link>. <ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%223%22])">3</ref><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%224%22])">4</ref><ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%225%22])">5</ref></p>

</ss1>
<ss1>
<st>
 Precautions/contraindications </st>

<p>

Propranolol should be used with caution in patients with:<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref></p>
<p>

<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../677/44677.xml">
Diabetes mellitus</link> or <link xlink:type="simple" xlink:href="../492/13492.xml">
hyperthyroidism</link>, since signs and symptoms of <link xlink:type="simple" xlink:href="../315/13315.xml">
hypoglycaemia</link> may be masked. Also, propranolol may affect blood sugar levels</entry>
<entry level="1" type="bullet">

<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../173/489173.xml">
Peripheral vascular disease</link></disease>
 and <link xlink:type="simple" xlink:href="../203/599203.xml">
Raynaud's syndrome</link>, which may be exacerbated</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../088/277088.xml">
Phaeochromocytoma</link>, as <link xlink:type="simple" xlink:href="../432/77432.xml">
hypertension</link> may be aggravated without prior <link xlink:type="simple" xlink:href="../667/18484667.xml">
alpha blocker</link> therapy</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../998/18998.xml">
Myasthenia gravis</link>, may be worsened</entry>
<entry level="1" type="bullet">

Other drugs with <link xlink:type="simple" xlink:href="../872/5872.xml">
bradycardic</link> effects</entry>
</list>
</p>
<p>

Propranolol is contraindicated in patients with:<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref></p>
<p>

<list>
<entry level="1" type="bullet">

Reversible airways disease, particularly <link xlink:type="simple" xlink:href="../905/44905.xml">
asthma</link> or <link xlink:type="simple" xlink:href="../033/63033.xml">
chronic obstructive pulmonary disease</link> (COPD)</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../872/5872.xml">
Bradycardia</link> (50 beats/minute)</entry>
<entry level="1" type="bullet">

<disease wordnetid="114070360" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../141/414141.xml">
Sick sinus syndrome</link></disease>
</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../933/2282933.xml">
Atrioventricular block</link> (second or third degree)</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../311/146311.xml">
Shock</link></entry>
<entry level="1" type="bullet">

Severe <link xlink:type="simple" xlink:href="../475/500475.xml">
hypotension</link></entry>
<entry level="1" type="bullet">

Uncontrolled <link xlink:type="simple" xlink:href="../930/249930.xml">
congestive heart failure</link></entry>
<entry level="1" type="bullet">

Cocaine toxicity [per American Heart Association guidelines, 2005]</entry>
</list>
</p>

</ss1>
<ss1>
<st>
 Adverse effects </st>
<p>

<link xlink:type="simple" xlink:href="../833/1274833.xml">
Adverse drug reaction</link>s (ADRs) associated with propranolol therapy are similar to other lipophilic beta blockers (<it>see <link xlink:type="simple" xlink:href="../150/180150.xml">
beta blocker</link></it>).</p>

</ss1>
<ss1>
<st>
 Pregnancy and lactation </st>
<p>

Propranolol, like other beta blockers, is classified as <link xlink:type="simple" xlink:href="../622/588622.xml">
Pregnancy category</link> C in the United States and <link xlink:type="simple" xlink:href="../367/2340367.xml">
ADEC</link> Category C in Australia. Beta-blocking agents in general reduce perfusion of the placenta which may lead to adverse outcomes for the <link xlink:type="simple" xlink:href="../304/349304.xml">
neonate</link>, including <link xlink:type="simple" xlink:href="../863/36863.xml">
pulmonary</link> or <link xlink:type="simple" xlink:href="../808/36808.xml">
cardiac</link> complications, or premature birth. The newborn may experience additional adverse effects such as <link xlink:type="simple" xlink:href="../315/13315.xml">
hypoglycemia</link> and <link xlink:type="simple" xlink:href="../872/5872.xml">
bradycardia</link>.</p>
<p>

Most beta-blocking agents appear in the milk of <link xlink:type="simple" xlink:href="../279/250279.xml">
lactating</link> women. This is especially the case for a <link xlink:type="simple" xlink:href="../745/596745.xml">
lipophilic</link> drug like propranolol. Breastfeeding is not recommended in patients receiving propranolol therapy.</p>

</ss1>
<ss1>
<st>
 Interactions </st>
<p>

Beta blockers, including propranolol, have an additive effect with other drugs which decrease blood pressure, or which decrease cardiac contractility or conductivity. Clinically-significant interactions particularly occur with:<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%221%22])">1</ref></p>
<p>

<list>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../963/525963.xml">
verapamil</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../250/10250.xml">
epinephrine</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../647/1708647.xml">
Î²2-adrenergic receptor agonists</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../643/556643.xml">
clonidine</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../512/621512.xml">
ergot alkaloid</link>s</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../849/2337849.xml">
isoprenaline</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../071/22071.xml">
non-steroidal anti-inflammatory drug</link>s</entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../411/640411.xml">
quinidine</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../112/1018112.xml">
cimetidine</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../762/298762.xml">
lidocaine</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../678/1588678.xml">
phenobarbital</link></entry>
<entry level="1" type="bullet">

<link xlink:type="simple" xlink:href="../146/928146.xml">
rifampicin</link></entry>
</list>
</p>

</ss1>
<ss1>
<st>
 Dosage </st>
<p>

The usual maintenance dose ranges for oral propranolol therapy vary by indication:</p>
<p>

<list>
<entry level="1" type="bullet">

Hypertension, angina, essential tremor</entry>
<entry level="2" type="bullet">

120â€“320 mg daily in divided doses. </entry>
<entry level="2" type="bullet">

Sustained-release formulations are available in some markets.</entry>
<entry level="1" type="bullet">

Tachyarrhythmia, anxiety, hyperthyroidism</entry>
<entry level="2" type="bullet">

10â€“40 mg 3â€“4 times daily</entry>
</list>
</p>
<p>

Intravenous (<link xlink:type="simple" xlink:href="../769/178769.xml">
IV</link>) propranolol may be used in acute <link xlink:type="simple" xlink:href="../562/5562.xml">
arrhythmia</link> or <link xlink:type="simple" xlink:href="../492/13492.xml">
thyrotoxic crisis</link>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%226%22])">6</ref></p>

</ss1>
<ss1>
<st>
Research into role against malaria</st>
<p>

Propranolol along with a number of other membrane-acting drugs have been investigated for possible effects on <it><link xlink:type="simple" xlink:href="../177/544177.xml">
P. falciparum</link></it> and so the treatment of <link xlink:type="simple" xlink:href="../423/20423.xml">
malaria</link>. In vitro positive effects until recently had not been matched by useful in vivo anti-parasite activity against <it><link>
P. vinckei</link></it>,<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%227%22])">7</ref> or <it><link xlink:type="simple" xlink:href="../946/6936946.xml">
P. yoelii nigeriensis</link></it>.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%228%22])">8</ref> However a single study from 2006 has suggested that propranolol may reduce the dosages required for existing drugs to be effective against <it>P. falciparum</it> by 5- to 10-fold, suggesting a role for combination therapies.<ref xlink:type="simple" xlink:href="#xpointer(//reflist/entry[@id=%229%22])">9</ref></p>

</ss1>
</sec>
<sec>
<st>
 References </st>

<p>

<reflist>
<entry id="1">
Rossi S, editor. <link xlink:type="simple" xlink:href="../871/1189871.xml">
Australian Medicines Handbook</link> 2006. Adelaide: Australian Medicines Handbook; 2006.</entry>
<entry id="2">
Sheetal Ladva&#32;(2006-06-28).&#32;"<weblink xlink:type="simple" xlink:href="http://www.nelm.nhs.uk/Record%20Viewing/viewRecord.aspx?id=567178">
NICE and BHS launch updated hypertension guideline</weblink>".&#32;  <link xlink:type="simple" xlink:href="../680/429680.xml">
National Institute for Health and Clinical Excellence</link>.&#32;Retrieved on <link>
2006-09-30</link>.</entry>
<entry id="3">
"<weblink xlink:type="simple" xlink:href="http://www.msnbc.msn.com/id/10806799/">
Doctors test a drug to ease traumatic memories - Mental Health - MSNBC.com</weblink>".&#32;Retrieved on <link>
2007-06-30</link>.</entry>
<entry id="4">
 <cite style="font-style:normal">Brunet A, Orr SP, Tremblay J, Robertson K, Nader K, Pitman RK&#32;(2007).&#32;"Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder": 503. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1016%2Fj.jpsychires.2007.05.006">
10.1016/j.jpsychires.2007.05.006</weblink>. PMID 17588604.</cite>&nbsp;</entry>
<entry id="5">
"<weblink xlink:type="simple" xlink:href="http://www.sciencedirect.com/science?_ob=ArticleURL&amp;_udi=B6T8T-4P1G931-2&amp;_user=10&amp;_coverDate=06%2F22%2F2007&amp;_alid=594818882&amp;_rdoc=1&amp;_fmt=summary&amp;_orig=search&amp;_cdi=5095&amp;_sort=d&amp;_docanchor=&amp;view=c&amp;_ct=1&amp;_acct=C000050221&amp;_version=1&amp;_urlVersion=0&amp;_userid=10&amp;md5=cff0ee031b688b5fbc74a7de54915c38">
Effect of post-retrieval propranolol on psychophysiologic responding during subsequent script-driven traumatic imagery in post-traumatic stress disorder</weblink>".</entry>
<entry id="6">
<list>
<entry level="1" type="bullet">

Joint Formulary Committee. <book wordnetid="106410904" confidence="0.9508927676800064">
<link xlink:type="simple" xlink:href="../142/124142.xml">
British National Formulary</link></book>
, 47th edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2004.</entry>
</list>
</entry>
<entry id="7">
 <cite style="font-style:normal">Ohnishi S, Sadanaga K, Katsuoka M, Weidanz W&#32;(1990).&#32;"Effects of membrane acting-drugs on plasmodium species and sickle cell erythrocytes". <it>Mol Cell Biochem</it>&#32;<b>91</b>&#32;(1-2): 159â€“65. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1007%2FBF00228091">
10.1007/BF00228091</weblink>. PMID 2695829.</cite>&nbsp;</entry>
<entry id="8">
 <cite style="font-style:normal">Singh N, Puri S&#32;(2000).&#32;"Interaction between chloroquine and diverse pharmacological agents in chloroquine resistant Plasmodium yoelii nigeriensis". <it>Acta Trop</it>&#32;<b>77</b>&#32;(2): 185â€“93. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1016%2FS0001-706X%2800%2900133-9">
10.1016/S0001-706X(00)00133-9</weblink>. PMID 11080509.</cite>&nbsp;</entry>
<entry id="9">
 <cite style="font-style:normal">Murphy S, Harrison T, Hamm H, Lomasney J, Mohandas N, Haldar K&#32;(Dec 2006).&#32;"Erythrocyte G protein as a novel target for malarial chemotherapy". <it>PLoS Med</it>&#32;<b>3</b>&#32;(12): e528. <document wordnetid="106470073" confidence="0.8">
<written_communication wordnetid="106349220" confidence="0.8">
<writing wordnetid="106362953" confidence="0.8">
<link xlink:type="simple" xlink:href="../994/422994.xml">
doi</link></writing>
</written_communication>
</document>
:<weblink xlink:type="simple" xlink:href="http://dx.doi.org/10.1371%2Fjournal.pmed.0030528">
10.1371/journal.pmed.0030528</weblink>. PMID 17194200.</cite>&nbsp;</entry>
</reflist>
</p>

</sec>
<sec>
<st>
 External links</st>
<p>

<list>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9456487&amp;dopt=Abstract">
Historical Remarks about Propranolol and its inventor</weblink></entry>
<entry level="1" type="bullet">

 <weblink xlink:type="simple" xlink:href="http://www.sciam.com/article.cfm?chanID=sa004&amp;articleID=0006783F-2CFE-1FE2-ACFE83414B7FFE9F&amp;pageNumber=1&amp;catID=4">
Scientific American Interview with James McGaugh</weblink></entry>
<entry level="1" type="bullet">

<weblink xlink:type="simple" xlink:href="http://www.cbsnews.com/stories/2006/11/22/60minutes/main2205629.shtml">
CBS NEWS 60 Minutes: A Pill To Forget</weblink></entry>
<entry level="1" type="bullet">

<weblink xlink:type="simple" xlink:href="http://papers.ssrn.com/sol3/papers.cfm?abstract_id=887061">
Therapeutic Forgetting: The Legal and Ethical Implications of Memory Dampening (Vanderbilt Law Review)</weblink></entry>
</list>
</p>

<p>

<table style=";" class="navbox" cellspacing="0">
<row>
<col style="padding:2px;">
<table style="width:100%;background:transparent;color:inherit;;" class="nowraplinks collapsible autocollapse " cellspacing="0">
<row>
<header colspan="2" style=";" class="navbox-title">
<link xlink:type="simple" xlink:href="../594/12653594.xml">
Adrenergic antagonist</link>s</header>
</row>
<row style="height:2px;">

</row>
<row>
<col style=";background:LightYellow;;" class="navbox-group">
<link xlink:type="simple" xlink:href="../667/18484667.xml">
Î±</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link xlink:type="simple" xlink:href="../722/2605722.xml">
Î±1 selective</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../986/2127986.xml">
Doxazosin</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../429/2257429.xml">
Prazosin</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../783/2294783.xml">
Alfuzosin</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../723/2409723.xml">
Terazosin</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../696/6833696.xml">
Indoramin</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../576/18486576.xml">
Urapidil</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../585/18486585.xml">
Trimazosin</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../878/12767878.xml">
Moxisylyte</link>&nbsp;Â·  <it><structure wordnetid="105225602" confidence="0.8">
<receptor wordnetid="105608868" confidence="0.8">
<part wordnetid="109385911" confidence="0.8">
<body_part wordnetid="105220461" confidence="0.8">
<link xlink:type="simple" xlink:href="../881/14288881.xml">
1A</link></body_part>
</part>
</receptor>
</structure>
</it> (<link xlink:type="simple" xlink:href="../934/2941934.xml">
Tamsulosin</link>, <link xlink:type="simple" xlink:href="../056/11219056.xml">
Silodosin</link>)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link xlink:type="simple" xlink:href="../744/18484744.xml">
Î±2 selective</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<physical_entity wordnetid="100001930" confidence="0.8">
<substance wordnetid="100020090" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="114778436" confidence="0.8">
<drug wordnetid="103247620" confidence="0.8">
<link xlink:type="simple" xlink:href="../189/16913189.xml">
Atipamezole</link></drug>
</agent>
</causal_agent>
</substance>
</physical_entity>
&nbsp;Â·  <link xlink:type="simple" xlink:href="../004/18485004.xml">
Efaroxan</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../001/14891001.xml">
Idazoxan</link>&nbsp;Â·  <plant wordnetid="103956922" confidence="0.8">
<structure wordnetid="104341686" confidence="0.8">
<artifact wordnetid="100021939" confidence="0.8">
<building_complex wordnetid="102914991" confidence="0.8">
<link xlink:type="simple" xlink:href="../845/780845.xml">
Yohimbine</link></building_complex>
</artifact>
</structure>
</plant>
&nbsp;Â·  <protagonist wordnetid="110172793" confidence="0.8">
<link xlink:type="simple" xlink:href="../861/1257861.xml">
Benzylpiperazine</link></protagonist>
&nbsp;Â·  <link xlink:type="simple" xlink:href="../478/2452478.xml">
Rauwolscine</link>&nbsp;Â·  <physical_entity wordnetid="100001930" confidence="0.8">
<substance wordnetid="100020090" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<medicine wordnetid="103740161" confidence="0.8">
<antidepressant wordnetid="102718811" confidence="0.8">
<agent wordnetid="114778436" confidence="0.8">
<drug wordnetid="103247620" confidence="0.8">
<link xlink:type="simple" xlink:href="../555/527555.xml">
Mirtazapine</link></drug>
</agent>
</antidepressant>
</medicine>
</causal_agent>
</substance>
</physical_entity>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
Non-selective Î±</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<it>reversible</it> (<link xlink:type="simple" xlink:href="../095/2860095.xml">
Phentolamine</link>)&nbsp;Â·  <it>irreversible</it> (<link xlink:type="simple" xlink:href="../999/2761999.xml">
Phenoxybenzamine</link>)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
Ungrouped</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../131/2860131.xml">
Tolazoline</link></col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:LightYellow;;" class="navbox-group">
<link xlink:type="simple" xlink:href="../150/180150.xml">
Î²</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<table style="width:100%;;;;" class="nowraplinks  navbox-subgroup" cellspacing="0">
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link>
Î²1 selective</link>(<it>cardioselective</it>)</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../313/712313.xml">
Atenolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../424/15344424.xml">
Celiprolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../518/1616518.xml">
Betaxolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../613/3391613.xml">
Bisoprolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../088/1116088.xml">
Esmolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../077/841077.xml">
Metoprolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../004/5448004.xml">
Nebivolol</link>&nbsp;Â·  <it><link xlink:type="simple" xlink:href="../710/791710.xml">
intrinsic sympatheticomimetic activity</link></it> (<link xlink:type="simple" xlink:href="../247/3337247.xml">
Acebutolol</link>)</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link>
Î²2 selective</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../469/7456469.xml">
Butaxamine</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../804/18850804.xml">
ICI 118551</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<structure wordnetid="105225602" confidence="0.8">
<receptor wordnetid="105608868" confidence="0.8">
<part wordnetid="109385911" confidence="0.8">
<body_part wordnetid="105220461" confidence="0.8">
<link>
Î²3 selective</link></body_part>
</part>
</receptor>
</structure>
</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../544/18853544.xml">
SR 59230A</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";padding-left:0em;padding-right:0em;background-color: LightYellow;" class="navbox-group">
<link>
Non-selective Î²</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<link xlink:type="simple" xlink:href="../869/14162869.xml">
Alprenolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../970/18591970.xml">
Amosulalol</link>&nbsp;Â·  <link>
Bupranolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../428/5771428.xml">
Metipranolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../433/984433.xml">
Nadolol</link>&nbsp;Â·  <substance wordnetid="100019613" confidence="0.8">
<compound wordnetid="114818238" confidence="0.8">
<methane_series wordnetid="114951377" confidence="0.8">
<chemical wordnetid="114806838" confidence="0.8">
<amine wordnetid="114739004" confidence="0.8">
<part wordnetid="113809207" confidence="0.8">
<organic_compound wordnetid="114727670" confidence="0.8">
<material wordnetid="114580897" confidence="0.8">
<aliphatic_compound wordnetid="114601294" confidence="0.8">
<link xlink:type="simple" xlink:href="../651/965651.xml">
Oxprenolol</link></aliphatic_compound>
</material>
</organic_compound>
</part>
</amine>
</chemical>
</methane_series>
</compound>
</substance>
&nbsp;Â·  <link xlink:type="simple" xlink:href="../673/4036673.xml">
Penbutolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../848/185848.xml">
Propranolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../990/15344990.xml">
Tertatolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../369/2402369.xml">
Timolol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../992/18590992.xml">
Tilisolol</link>&nbsp;Â·  <physical_entity wordnetid="100001930" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<link xlink:type="simple" xlink:href="../343/936343.xml">
Sotalol</link></agent>
</causal_agent>
</physical_entity>
&nbsp;Â·  <it><link xlink:type="simple" xlink:href="../710/791710.xml">
intrinsic sympatheticomimetic activity</link></it> (<link xlink:type="simple" xlink:href="../881/1480881.xml">
Pindolol</link>)</col>
</row>
</table>
</col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:LightYellow;;" class="navbox-group">
<link>
Mixed Î±
1/Î²</link></col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<link xlink:type="simple" xlink:href="../521/3464521.xml">
Carvedilol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../436/3260436.xml">
Labetalol</link>&nbsp;Â·  <link xlink:type="simple" xlink:href="../379/18606379.xml">
Arotinolol</link></col>
</row>
<row style="height:2px">

</row>
<row>
<col style=";background:LightYellow;;" class="navbox-group">
Indirect</col>
<col style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<it><link xlink:type="simple" xlink:href="../039/4943039.xml">
tyrosine hydroxylase inhibitor</link></it> (<physical_entity wordnetid="100001930" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<link xlink:type="simple" xlink:href="../782/6979782.xml">
Metirosine</link></agent>
</causal_agent>
</physical_entity>
)&nbsp;Â·  <it><link xlink:type="simple" xlink:href="../320/780320.xml">
vesicle</link> storage inhibitor</it> (<physical_entity wordnetid="100001930" confidence="0.8">
<substance wordnetid="100020090" confidence="0.8">
<substance wordnetid="100019613" confidence="0.8">
<alkaloid wordnetid="114712692" confidence="0.8">
<compound wordnetid="114818238" confidence="0.8">
<chemical wordnetid="114806838" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<part wordnetid="113809207" confidence="0.8">
<organic_compound wordnetid="114727670" confidence="0.8">
<inhibitor wordnetid="114724436" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<material wordnetid="114580897" confidence="0.8">
<link xlink:type="simple" xlink:href="../766/1480766.xml">
Reserpine</link></material>
</agent>
</inhibitor>
</organic_compound>
</part>
</causal_agent>
</chemical>
</compound>
</alkaloid>
</substance>
</substance>
</physical_entity>
)&nbsp;Â·  <it>neurotransmitter release blocker</it> (<link xlink:type="simple" xlink:href="../500/4959500.xml">
Guanethidine</link>, <physical_entity wordnetid="100001930" confidence="0.8">
<causal_agent wordnetid="100007347" confidence="0.8">
<agent wordnetid="109190918" confidence="0.8">
<link xlink:type="simple" xlink:href="../445/5047445.xml">
Bretylium</link></agent>
</causal_agent>
</physical_entity>
)</col>
</row>
</table>
</col>
</row>
</table>
</p>



</sec>
</bdy>
</agent>
</invention>
</article>
